BiotechTube

YHD1119 + Lyrica

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peripheral Neuropathic Pain

Conditions

Peripheral Neuropathic Pain

Trial Timeline

Feb 7, 2017 → May 2, 2018

NCT ID
NCT02985216

About YHD1119 + Lyrica

YHD1119 + Lyrica is a phase 3 stage product being developed by Yuhan for Peripheral Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02985216. Target conditions include Peripheral Neuropathic Pain.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT02985216Phase 3Completed
NCT02783183Phase 1Completed
NCT02783638Phase 1Completed

Competing Products

20 competing products in Peripheral Neuropathic Pain

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
LY3857210 + PlaceboEli LillyPhase 2
52
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
85
YHD1119 + LyricaYuhanPhase 1
33
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
85
YHD1119 + LyricaYuhanPhase 1
33
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
33
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
52
edoxaban + Clopidogrel + AspirinDaiichi SankyoPhase 2
52
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
Valemetostat TosylateDaiichi SankyoPhase 2
52
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
52
QutenzaAstellas PharmaPre-clinical
23
QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
85
Qutenza exposureAstellas PharmaPre-clinical
23
QUTENZAAstellas PharmaPhase 3
77
Qutenza + PregabalinAstellas PharmaApproved
85
Capsaicin 8% + PlaceboAstellas PharmaPhase 3
77

Other Products from Yuhan

generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85